Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study (Q34046624)

30 July 2017

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study (English)

1 reference

30 July 2017

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Bruno Quesnel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Claude Preudhomme

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

9

Christophe Roumier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

2

Emmanuel Raffoux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

13

Mauricette Michallet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

4

Norbert Vey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

14

Christian Recher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Céline Berthon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Xavier Thomas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Carlos Gomez-Roca

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Karen Yee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

David Christopher Taussig

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Patrice Herait

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Carmen Kahatt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

François Lokiec

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Hervé Dombret

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

1 reference

18 March 2016

1 reference

30 July 2017

The Lancet. Haematology.

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

e186-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

The role of mutations in epigenetic regulators in myeloid malignancies

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Epigenetic alterations in acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Targeting bromodomains: epigenetic readers of lysine acetylation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Selective inhibition of tumor oncogenes by disruption of super-enhancers

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Selective inhibition of BET bromodomains

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Disordered epigenetic regulation in MLL-related leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2815%2900247-1

7 January 2021

10.1016/S2352-3026(15)00247-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27063977%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference